e-learning
resources
Milan 2017
Wednesday, 13.09.2017
Idiopathic pulmonary fibrosis: from the bench to the bedside
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis
C. Moor (Rotterdam, Netherlands)
Source:
International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Session:
Idiopathic pulmonary fibrosis: from the bench to the bedside
Session type:
Poster Discussion
Number:
4884
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Moor (Rotterdam, Netherlands). Discrepancy between patient expectations and experiences with anti-fibrotic drugs in idiopathic pulmonary fibrosis. 4884
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Comorbidities influence in idiopathic pulmonary fibrosis antifibrotic treatments
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019
Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes
Source: Eur Respir Rev 2012; 21: 161-167
Year: 2012
Patients’ expectations and quality of life before introduction of pirfenidone used in idiopathic pulmonary fibrosis.
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Year: 2018
Antifibrotic choice in idiopathic pulmonary fibrosis
Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF)
Year: 2018
Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis
Source: Eur Respir J, 54 (6) 1901188; 10.1183/13993003.01188-2019
Year: 2019
Clinical burden of idiopathic pulmonary fibrosis (IPF): physician and patient perception
Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis
Year: 2020
Antithrombotics in idiopathic pulmonary fibrosis patients with concomitant antifibrotic therapy: a single centre real world experience
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Tolerability and safety of anti-fibrotic agents for idiopathic pulmonary fibrosis in real world
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation
Source: Eur Respir J 2012; 40: 794-795
Year: 2012
Factors affecting the compliance to antifibrotic treatment in patients with interstitial pulmonary fibrosis
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 58-64
Year: 2015
Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence?
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
The development of a measure to better understand patient experiences with pirfenidone and nintedanib for the treatment of idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Efficacy of switching antifibrotic therapy in idiopathic pulmonary fibrosis: real life data
Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis
Year: 2019
Generalisability of recent clinical trials in idiopathic pulmonary fibrosis to everyday clinical practice
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Source: Eur Respir Rev, 26 (146) 170057; 10.1183/16000617.0057-2017
Year: 2017
Current and future therapeutic approaches in idiopathic pulmonary fibrosis
Source: Eur Respir J 2005; 26: 693-703
Year: 2005
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept